Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Finance
Molecular biotechnology company posts narrowed quarterly loss
September 14th, 2005
GeneThera, Inc., (GTHA) announced that it has narrowed its second-quarter loss to $0.02 per share from prior-year loss of $.70 per share. The molecular biotechnology company reported a loss of $316,900, or 2 cents a share, for the 3-month period ended June 30, 2005. That compares with a $3,989,000 net loss, or 70 cents a share in the year-earlier period, GeneThera said in a statement. Steven M. Grubner, GeneThera CFO, said, "We are extremely pleased to have narrowed our quarterly loss to under 2 cents per share. Our use of internal resources and personnel instead of outside consultants has had a tremendous impact on our bottom line. Having proper...
Source: Vaccine Weekly (2005-09-14)
|
